Accelerated Approval Price Caps: Policy Has High Profile Support – But Can It Be Done?
Executive Summary
US Medicare Payment Advisory Commission likely to recommend that drugs granted Accelerated Approval be subject to some form of price cap when confirmatory clinical data is lacking. The idea has a lot of supporters, but even they seem a bit unclear about how it could actually work.
You may also be interested in...
FDA’s Califf Defends CMS Drug Coverage Role, Blames Rx Industry Prices For US Health Woes
US FDA Commissioner defends role of his sister-agency CMS in determining drug coverage after his agency’s approvals. Califf weighs in on a variety of drug pricing topics – including the IRA, accelerated approval pricing, and obesity drug coverage – at the annual BIO meeting in Boston.
FDA’s Califf Defends CMS Drug Coverage Role, Blames Rx Industry Prices For US Health Woes
US FDA Commissioner defends role of his sister-agency CMS in determining drug coverage after his agency’s approvals. Califf weighs in on a variety of drug pricing topics – including the IRA, accelerated approval pricing, and obesity drug coverage – at the annual BIO meeting in Boston.
Private Payers Have ‘Significant’ Role In Ensuring Confirmatory Trials Get Done, FDA’s Califf Says
In an unusual appearance at AHIP annual conference on Medicare and Medicaid, the US FDA commissioner discusses accelerated approvals and argues that payers should be more than ‘passive recipients’ of research. Insurers should help develop the confirmatory data for drugs, Califf says.